Literature DB >> 24114738

Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects.

Arna S Desser1, Jan Abel Olsen, Sverre Grepperud.   

Abstract

BACKGROUND: Understanding societal preferences regarding resource allocation in the health sector has gained importance as countries increasingly base reimbursement decisions on economic evaluations. Preference elicitation using surveys, a common practice in the health sector, is subject to a range of framing effects.
OBJECTIVE: This research investigates the importance of (theoretically relevant) opportunity costs and (theoretically irrelevant) framing effects on stated preferences for prioritizing treatment of rare (orphan) diseases.
METHODS: We elicited preferences from Norwegians, aged 40-67, using simple trade-off exercises. Respondents were randomised to different opportunity costs of the rare disease or to different framings of the trade-off exercises.
RESULTS: Respondents were quite sensitive to the visual presentation of the choice problem, and, to a lesser extent, to focusing and labelling effects. Elicited preferences varied little in response to large changes in opportunity costs, suggesting scope-insensitivity among respondents.
CONCLUSIONS: Preferences for prioritizing treatment of rare diseases elicited using trade-off exercises are insensitive to (theoretically relevant) opportunity costs, but sensitive to (theoretically irrelevant) framing effects.

Entities:  

Mesh:

Year:  2013        PMID: 24114738     DOI: 10.1007/s40273-013-0093-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  11 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Preferences for the normative basis of health care priority setting: some evidence from two countries.

Authors:  Jan Abel Olsen; Jeff Richardson
Journal:  Health Econ       Date:  2012-02-23       Impact factor: 3.046

3.  Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.

Authors:  Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
Journal:  J Med Econ       Date:  2010       Impact factor: 2.448

Review 4.  Orphan drugs and the NHS: should we value rarity?

Authors:  Christopher McCabe; Karl Claxton; Aki Tsuchiya
Journal:  BMJ       Date:  2005-10-29

Review 5.  Drugs for exceptionally rare diseases: do they deserve special status for funding?

Authors:  D A Hughes; B Tunnage; S T Yeo
Journal:  QJM       Date:  2005-10-03

6.  On the elicitation of preferences for alternative therapies.

Authors:  B J McNeil; S G Pauker; H C Sox; A Tversky
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

7.  The framing of decisions and the psychology of choice.

Authors:  A Tversky; D Kahneman
Journal:  Science       Date:  1981-01-30       Impact factor: 47.728

8.  Assessing the economic challenges posed by orphan drugs.

Authors:  Michael F Drummond; David A Wilson; Panos Kanavos; Peter Ubel; Joan Rovira
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

9.  Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67.

Authors:  Arna S Desser; Dorte Gyrd-Hansen; Jan Abel Olsen; Sverre Grepperud; Ivar Sønbø Kristiansen
Journal:  BMJ       Date:  2010-09-22

10.  The default effect in end-of-life medical treatment preferences.

Authors:  Laura M Kressel; Gretchen B Chapman
Journal:  Med Decis Making       Date:  2007 May-Jun       Impact factor: 2.583

View more
  5 in total

1.  Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.

Authors:  Nick Dragojlovic; Shirin Rizzardo; Nick Bansback; Craig Mitton; Carlo A Marra; Larry D Lynd
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

2.  Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey.

Authors:  Jeff Richardson; Angelo Iezzi; Gang Chen; Aimee Maxwell
Journal:  Pharmacoecon Open       Date:  2017-03

3.  Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia.

Authors:  Lesley Chim; Glenn Salkeld; Patrick Kelly; Wendy Lipworth; Dyfrig A Hughes; Martin R Stockler
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

4.  Does moral reasoning influence public values for health care priority setting?: A population-based randomized stated preference survey.

Authors:  Avram E Denburg; Wendy J Ungar; Shiyi Chen; Jeremiah Hurley; Julia Abelson
Journal:  Health Policy       Date:  2020-05-13       Impact factor: 2.980

Review 5.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.